Brolucizumab Brand Name– BEOVU
What is Brolucizumab
Brolucizumab is a human vascular endothelial growth factor (VEGF) inhibitor approved for the treatment of neovascular (wet) age-related macular degeneration (AMD).
The drug is administered via intravitreal injection and must be given under aseptic conditions by a qualified physician.
The initial 3 doses are administered monthly (approximately every 25 to 31 days), after which the dosing interval may be extended to every 8 to 12 weeks.
Brolucizumab is contraindicated for use in patients with ocular or periocular infections and patients with active intraocular inflammation. Instruct patients to immediately report if ocular pain, redness of the eye, photophobia, or blurred vision occurs as these may be signs of a detached retina or of an eye infection.
Indications
- macular degeneration
For the treatment of neovascular (wet) age-related macular degeneration (AMD)
Side Effects
- antibody formation
- blurred vision
- cataracts
- conjunctival hyperemia
- conjunctivitis
- corneal erosion
- endophthalmitis
- erythema
- foreign body sensation
- iritis
- keratitis
- lacrimation
- myocardial infarction
- ocular hemorrhage
- ocular hypertension
- ocular infection
- ocular inflammation
- ocular pain
- pruritus
- rash
- retinal detachment
- retinal hemorrhage
- stroke
- thromboembolism
- urticaria
- uveitis
- visual impairment
Monitoring Parameters
- intraocular pressure
Contraindications
- breast-feeding
- children
- contraception requirements
- driving or operating machinery
- increased intraocular pressure
- infants
- infertility
- neonates
- ocular infection
- ocular inflammation
- pregnancy
- reproductive risk
- retinal detachment
- thromboembolic disease
Interactions
There are no drug interactions associated with Brolucizumab products.
